Thursday, February 26, 2009

Combination sonodynamic therapy with immunoadjuvant may be a promising new modality for cancer treatment


Copyright © 2008 Elsevier Ltd All rights reserved.

Combination sonodynamic therapy with immunoadjuvant may be a promising new modality for cancer treatment

Purchase the full-text article

Xiaopeng Maa, 1, Huixuan Panb, 1 and Jilin Yia, Corresponding Author Contact Information, E-mail The Corresponding Author, E-mail The Corresponding Author

aDepartment of Breast and Thyroid Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

bDepartment of Nephrology, First Affiliated Hospital, School of Medicine, Yangtze University, Jingzhou 434000, China

Received 23 September 2008;
accepted 2 October 2008.
Available online 6 January 2009.


Sonodynamic therapy (SDT) is a new cancer therapy basing on photodynamic therapy (PDT). Some chemicals produce free radicals on irradiation with laser (photosensitizers) or ultrasound (sonosensitizers). These active molecules destroy biological tissues, thus producing therapeutic effects. Although PDT has been adopted in clinical cancer therapy especially for superficial cancers, this modality is under continued investigation for improved efficacy and expanded use. For example, PDT-generated tumor cell lysates are effective cancer vaccines; treatment of PDT in conjunction with immunoadjuvant, called “PDT-immunoadjuvant therapy” (PIT), “photoimmunotherapy” or “laser immunotherapy”, is considered to be a promising therapeutic interventions for the treatment of cancers. Ultrasound, especially focused ultrasound, can penetrate deeply into tissues and can be focused into a small region of a tumor to activate the cytotoxicity of sonosensitizers. This is a unique advantage in the non-invasive treatment of nonsuperficial tumors when compared to laser light used for PDT. For the similar mechanism of PDT and SDT, we hypothesize that SDT may be exploited for the generation of effective therapeutic cancer vaccines like PDT; and combination SDT with Immunoadjuvant may be a promising systemic treatment modality, not only for superficial cancers but also for deep-seated tumors, which would surpass PIT.
Article Outline

The similar principle, process, drugs and mechanism of PDT and SDT
PDT-generated tumor cell lysates (in vitro) are effective cancer vaccines
‘‘PDT-immunoadjuvant therapy” forms an in situ autovaccine
The unique advantage of ultrasound
Future perspectives

Corresponding Author Contact InformationCorresponding author. Tel.: +86 27 83663818; fax: +86 27 83662851.
1 These authors contributed equally to this study.